Trials / Completed
CompletedNCT03481946
A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia
A Phase 1 Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the pharmacokinetics in patients with severe hemophilia. The secondary objective is to assess the pharmacodynamics of BAY1093884 based on tissue factor pathway inhibitor activity
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BAY1093884 | 0.3 mg/kg given intravenously |
| DRUG | BAY1093884 | 1 mg/kg given intravenously |
Timeline
- Start date
- 2018-05-10
- Primary completion
- 2018-10-17
- Completion
- 2019-02-20
- First posted
- 2018-03-29
- Last updated
- 2020-09-16
Locations
1 site across 1 country: Israel
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03481946. Inclusion in this directory is not an endorsement.